OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.228
-0.068 (-2.06%)
Jul 14, 2026, 10:11 AM CET
OSE Immunotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Tedopi, a neoepitope-based immunotherapy, demonstrated improved survival and safety over docetaxel in NSCLC and showed a 50% reduction in progression risk when combined with pembrolizumab in platinum-sensitive ovarian cancer. Rapid adoption is anticipated if phase III results are positive, with further combination strategies under consideration.
Fiscal Year 2025
-
A new management team has launched a strategic plan focused on maximizing value from Tedopi and Lusvertikimab, with four key levers and a balanced financial strategy targeting EUR 90 million over three years. Clinical progress and partnership discussions are ongoing, with a focus on market-driven formulations and rare disease indications.